Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Henan Cancer Hospital
Institut Paoli-Calmettes
Shanghai Simnova Biotechnology Co.,Ltd.
Alliance for Clinical Trials in Oncology
University Hospital Ostrava
Radiotherapy Oncology Centre "Santa Maria" Hospital
Jiangsu Cancer Institute & Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Peking Union Medical College Hospital
Fudan University
Ruijin Hospital
Henan Cancer Hospital
Fondazione IRCCS Policlinico San Matteo di Pavia
Henan Cancer Hospital
Zhejiang University
Zhongnan Hospital
Institut Paoli-Calmettes
Seoul National University Hospital
Salah Azaïz Cancer Institute
Universitätsklinikum Hamburg-Eppendorf
Yixing People's Hospital
Tianjin Medical University Cancer Institute and Hospital
Xijing Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Yantai Yuhuangding Hospital
Yantai Yuhuangding Hospital
National Cancer Institute, Naples
Instituto do Cancer do Estado de São Paulo
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sun Yat-sen University
Shanghai Chest Hospital
Shanghai Zhongshan Hospital
Henan Provincial People's Hospital
Henan Provincial People's Hospital
Zhongda Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Campus Bio-Medico University
Brigham and Women's Hospital
Xijing Hospital
Second Xiangya Hospital of Central South University
Fudan University
King Abdullah Medical City
Shanghai Zhongshan Hospital
Chinese PLA General Hospital
The Affiliated Hospital of Xuzhou Medical University
Immunicom Inc
Peking Union Medical College Hospital